James M. Rae
About
James M. Rae is a scholar working on Oncology, Genetics and Molecular Biology.
According to data from OpenAlex, James M. Rae has authored 148 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 73 papers in Genetics and 45 papers in Molecular Biology. Recurrent topics in James M. Rae's work include Estrogen and related hormone effects (69 papers), Pharmacogenetics and Drug Metabolism (36 papers) and Breast Cancer Treatment Studies (26 papers). James M. Rae is often cited by papers focused on Estrogen and related hormone effects (69 papers), Pharmacogenetics and Drug Metabolism (36 papers) and Breast Cancer Treatment Studies (26 papers). James M. Rae collaborates with scholars based in United States, United Kingdom and Australia. James M. Rae's co-authors include David A. Flockhart, Michael D. Johnson, Marc E. Lippman, Zeruesenay Desta, Daniel F. Hayes, Todd C. Skaar, Vered Stearns, Chad J. Creighton, Joshua O. Scheys and Anne Nguyen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of the American College of Cardiology.
In The Last Decade
James M. Rae
144 papers receiving 6.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| James M. Rae United States | 40 | 2.9k | 2.8k | 2.4k | 2.1k | 1.5k | 148 | 6.8k | ||
| Hiltrud Brauch Germany | 40 | 1.7k 0.6× | 2.3k 0.8× | 966 0.4× | 3.4k 1.6× | 2.4k 1.6× | 162 | 6.8k | ||
| Ernst A. Lien Norway | 37 | 2.0k 0.7× | 1.3k 0.5× | 790 0.3× | 930 0.4× | 646 0.4× | 81 | 4.1k | ||
| Cristina Rodríguez‐Antona Spain | 39 | 483 0.2× | 2.1k 0.7× | 2.0k 0.8× | 2.2k 1.0× | 1.1k 0.8× | 137 | 6.0k | ||
| David D. McKee United States | 22 | 2.7k 0.9× | 3.8k 1.4× | 2.8k 1.2× | 3.6k 1.7× | 441 0.3× | 24 | 8.9k | ||
| V. Craig Jordan United States | 57 | 7.3k 2.5× | 3.3k 1.2× | 724 0.3× | 4.1k 1.9× | 2.1k 1.4× | 159 | 11.3k | ||
| Angela Brodie United States | 52 | 4.2k 1.4× | 1.7k 0.6× | 818 0.3× | 3.2k 1.5× | 1.2k 0.8× | 132 | 7.8k | ||
| Kaname Kawajiri Japan | 44 | 1.0k 0.3× | 1.2k 0.4× | 2.0k 0.8× | 3.9k 1.8× | 1.8k 1.2× | 76 | 6.8k | ||
| Stephen F. Madden Ireland | 47 | 688 0.2× | 2.2k 0.8× | 516 0.2× | 4.8k 2.2× | 1.4k 0.9× | 164 | 8.1k | ||
| Andrea DeCensi Italy | 51 | 2.7k 0.9× | 3.7k 1.3× | 312 0.1× | 4.0k 1.9× | 2.5k 1.7× | 246 | 9.2k | ||
| Leszek Wojnowski Germany | 39 | 586 0.2× | 1.8k 0.7× | 1.9k 0.8× | 2.5k 1.2× | 373 0.3× | 93 | 6.1k |
Countries citing papers authored by James M. Rae
Since
Specialization
Citations
This map shows the geographic impact of James M. Rae's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Rae with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Rae more than expected).
Fields of papers citing papers by James M. Rae
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by James M. Rae. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Rae. The network helps show where James M. Rae may publish in the future.
Co-authorship network of co-authors of James M. Rae
This figure shows the co-authorship network connecting the top 25 collaborators of James M. Rae. A scholar is included among the top collaborators of James M. Rae based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Rae. James M. Rae is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bryant, Alex K., Yuewei Lin, James M. Rae, et al.. (2024). Artificial intelligence to unlock real‐world evidence in clinical oncology: A primer on recent advances. Cancer Medicine. 13(12). e7253–e7253.
2.
Pusztai, Lajos, Kathy S. Albain, William E. Barlow, et al.. (2024). Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer. Journal of Clinical Oncology. 43(8). 919–928.
3.
Gersch, Christina L., N. Lynn Henry, Karen L. Smith, et al.. (2024). Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms. Pharmacogenetics and Genomics. 34(4). 126–129.
4.
Speers, Corey, W. Fraser Symmans, William E. Barlow, et al.. (2023). Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Journal of Clinical Oncology. 41(10). 1841–1848.
5.
Bergqvist, Mattias, Costanza Paoletti, William E. Barlow, et al.. (2023). Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers. 28(3). 313–322.
6.
Michmerhuizen, Anna R., Rachel Schwartz, Kari Wilder-Romans, et al.. (2022). Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. British Journal of Cancer. 127(5). 927–936.
7.
Chandler, Benjamin C., Anna R. Michmerhuizen, Kari Wilder-Romans, et al.. (2022). Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression. Cancer Research Communications. 2(7). 679–693.
8.
Michmerhuizen, Anna R., Rachel Schwartz, Kari Wilder-Romans, et al.. (2022). Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. npj Breast Cancer. 8(1). 31–31.
9.
Hertz, Daniel L., Julie A. Douglas, Robert M. Miller, et al.. (2022). Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. Supportive Care in Cancer. 30(10). 8059–8067.
10.
Michmerhuizen, Anna R., Kari Wilder-Romans, Benjamin C. Chandler, et al.. (2021). RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes. JCI Insight. 7(3).
11.
Pasternak, Amy L., Vincent D. Marshall, Christina L. Gersch, et al.. (2021). Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus. Pharmacogenomics and Personalized Medicine. Volume 14. 319–326.
12.
Poznak, Catherine Van, Evan L. Reynolds, Cherry L. Estilo, et al.. (2020). Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer. Oral Diseases. 28(1). 193–201.
13.
Chandler, Benjamin C., Anna R. Michmerhuizen, Kari Wilder-Romans, et al.. (2020). Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers. Clinical Cancer Research. 26(24). 6568–6580.
14.
Chan, June M., Amy K. Darke, Kathryn L. Penney, et al.. (2016). Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers & Prevention. 25(7). 1050–1058.
15.
Santa‐Maria, Cesar A., Amanda L. Blackford, Anne Nguyen, et al.. (2015). Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. Clinical Cancer Research. 22(6). 1395–1402.
16.
Paoletti, Costanza, Maria C. Muñiz, Dafydd G. Thomas, et al.. (2014). Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 21(11). 2487–2498.
17.
Hayes, Daniel F., Todd C. Skaar, James M. Rae, et al.. (2010). Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated Results. Clinical Pharmacology & Therapeutics. 88(5). 626–629.
18.
Rae, James M., Susan J. Ramus, Mark Waltham, et al.. (2004). Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Queensland's institutional digital repository (The University of Queensland).
19.
Rae, James M., et al.. (2002). Thiotepa is a specific inhibitor of cytochrome P450 2B6 Implications for cyclophosphamide metabolism. Clinical Pharmacology & Therapeutics. 71(2). 28.
20.
Flockhart, David A., et al.. (2001). Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner. Clinical Pharmacology & Therapeutics. 69(2).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hiltrud Brauch Breakdown of academic impact, for papers by Ernst A. Lien Breakdown of academic impact, for papers by Cristina Rodríguez‐Antona Breakdown of academic impact, for papers by David D. McKee Breakdown of academic impact, for papers by V. Craig Jordan Breakdown of academic impact, for papers by Angela Brodie Breakdown of academic impact, for papers by Kaname Kawajiri Breakdown of academic impact, for papers by Stephen F. Madden Breakdown of academic impact, for papers by Andrea DeCensi Breakdown of academic impact, for papers by Leszek Wojnowski